[关键词]
[摘要]
利伐沙班作为一种特异性凝血因子Xa抑制剂在临床上被广泛应用于抗凝的预防及治疗中。然而,在临床应用过程中,利伐沙班与其他药物合用所致的出血风险仍需密切监视。聚焦药物代谢酶及转运体,分别从利伐沙班与心血管系统药物、抗肿瘤药物、以及代谢靶点相关药物合用等方面系统综述药动学介导的利伐沙班相关药物-药物相互作用的研究进展,旨在为利伐沙班的临床安全合理用药提供更科学、更直接的指导依据。
[Key word]
[Abstract]
Rivaroxaban as a specific Xa inhibitor is widely applied to the prevention and treatment of clinical anticoagulation. However, the risk of bleeding caused by the combination of rivaroxaban with other drugs still needs to be closely monitored in clinical application. This review focuses on the metabolic enzymes and transporters, systematically summarizes the progress of rivaroxaban related DDIs mediated by pharmacokinetics from the aspects of the applications combined with cardiovascular drugs, anti-cancer drugs and drugs related to metabolic targets and so on, aiming to provide more significant and direct guidance for rivaroxaban clinical application.
[中图分类号]
[基金项目]
国家自然科学基金资助项目(81874324);辽宁省兴辽英才青年拔尖人才项目(XLYC1907103)